Philippe Pouletty - Innate Pharma Independent Member of the Supervisory Board
| IPH Stock | EUR 2.17 0.06 2.84% |
Executive
Dr. Philippe Pouletty was Independent Member of the Supervisory Board at Innate Pharma SA since December 22, 2001. He is CoFounder and Chief Executive Officer of Truffle Capital, Chairman and Founder of Deinove, CoFounder and Member of the Board of Directors of Carmat, former Chairman and Board Member, Chairman of BMD Splicos, CoFounder and Board Member of Pharnext, Plasmaprime, Vexim and Wittycell, Board Member of Immune Targeting Systems, Myopowers, Symetis and Theraclion, as well as Founder of SangStat and Conjuchem. Dr. Pouletty also served as Chairman of France Biotech, a French biotechnology association, and currently is its Honorary Chairman. In addition, he was Vice Chairman of Europabio, the European Biotechnology Association. Dr. Pouletty previously contributed to various governmental Laws in France, including the 1999 Law to simplify the legal status of companies, the 2002 Biotech plan to increase the development of biotechnology, and the setting up of tax exemptions for young innovating companies since 2001.
| Age | 55 |
| Tenure | 23 years |
| Professional Marks | Ph.D |
| Phone | 33 4 30 30 30 30 |
| Web | https://www.innate-pharma.com |
Innate Pharma Management Efficiency
The company has return on total asset (ROA) of (0.043) % which means that it has lost $0.043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1731) %, meaning that it generated substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | EXECUTIVE Age | ||
| Philippe Moons | Genfit | N/A | |
| Florence Sejourne | Genfit | N/A | |
| Frederic Desdouits | Genfit | N/A | |
| Stephan Reynier | Cellectis | N/A | |
| MarieBleuenn Terrier | Cellectis | 41 | |
| Philippe Duchateau | Cellectis | 60 | |
Management Performance
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 |
Innate Pharma Leadership Team
Elected by the shareholders, the Innate Pharma's board of directors comprises two types of representatives: Innate Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innate. The board's role is to monitor Innate Pharma's management team and ensure that shareholders' interests are well served. Innate Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innate Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Butler, Executive Vice President General Manager, US | ||
| Odile Belzunce, VP Operations | ||
| Eric Vivier, Chief Scientific Officer | ||
| Jean Fourni, Founder | ||
| Irina StaatzGranzer, Vice Chairman and Independent Member of the Supervisory Board | ||
| DVM MBA, VP Founder | ||
| Frederic MBA, VP CFO | ||
| Mondher MD, Chairman CEO | ||
| Herve Brailly, Chairman of the Management Board, Member of the Executive Committee, CEO | ||
| Jerome Tiollier, Member of the Executive Board, Executive Vice President - Development | ||
| Karsten Knudsen, Member of the Supervisory Board - Representative of Novo Nordisk AG | ||
| Mondher Mahjoubi, Chairman of the Executive Board, CEO | ||
| Nicolai Wagtmann, Chief Scientific Officer, Executive VP and Member of Executive Board | ||
| JeanYves Blay, Member of the Supervisory Board | ||
| JeanCharles Soria, Member of the Supervisory Board | ||
| Gilles Brisson, Chairman and Independent Member of the Supervisory Board | ||
| LaureHelene Mercier, Director of Investor Relations | ||
| Marc Bonneville, Founder | ||
| Catherine Moukheibir, Member of the Executive Committee, Executive Vice President Member of the Management Board - Consultant Senior Finance Advisor | ||
| Patrick Langlois, Member of the Supervisory Board | ||
| Marcus Schindler, Member of the Supervisory Board, Representative of Novo Nordisk | ||
| Alessandro MD, Founder | ||
| Veronique Chabernaud, Member of the Supervisory Board | ||
| Marcel Rozencweig, Member of the Executive Committee, Executive Vice President | ||
| Michael Caligiuri, Member of the Supervisory Board | ||
| Pierre Dodion, Member of the Executive Committee, Chief Medical Officer | ||
| Mailys Ferrere, Member of the Supervisory Board | ||
| Yannis Morel, Member of the Executive Committee, Executive Vice President Business Development | ||
| Philippe Pouletty, Independent Member of the Supervisory Board | ||
| Franois Romagn, Founder |
Innate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innate Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 86.87 M | |||
| Shares Outstanding | 80.2 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 125.20 X | |||
| Price To Book | 1.43 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.Note that the Innate Pharma information on this page should be used as a complementary analysis to other Innate Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |